Thu, Nov 21, 2024
[Archive]
Volume 31, Issue 147 (July & August 2023)
J Adv Med Biomed Res 2023, 31(147): 348-357 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rezaieyazdi Z, Sahebari M, Fatehi Z, Khodashahi R, Khodashahi M. Comparison of Quality of Life in Patients with Systemic Lupus Erythematosus and Healthy Controls in North-East of Iran. J Adv Med Biomed Res 2023; 31 (147) :348-357
URL: http://journal.zums.ac.ir/article-1-6936-en.html
URL: http://journal.zums.ac.ir/article-1-6936-en.html
1- Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2- Dept. of Infectious Diseases and Tropical Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3- Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran ,mkhodashahi53@gmail.com
2- Dept. of Infectious Diseases and Tropical Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3- Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran ,
Abstract: (1328 Views)
Background and Objective: Genetic modifications in the adiponectin receptor 2 (AdipoR2) gene can affect phenotypes associated with insulin resistance and diabetes. The purpose of this study was to evaluate the possible role of genetic modifications in the AdipoR2 gene, to determine the frequency of genotypes and polymorphism alleles of this gene at rs11061971 (+219 A>T), and to investigate its correlation with type 2 diabetes (T2D) and its related metabolic profile.
Materials and Methods: In this case-control study, the single-nucleotide polymorphism (SNP) of AdipoR2 in 116 T2D patients and 102 controls was evaluated using RFLP PCR and FOK 1 enzyme. Fasting blood sugar, cholesterol, triglyceride, insulin, HDL-C, LDL-C and HbA1c were also measured and their correlation with the studied genetic modifications was assessed. The collected data were analyzed using Chi-square test and Hardy-Weinberg equation.
Results: There was a significant association in AT and TT genotypes in rs11061971 (+219 A>T) with T2D. However, no significant difference was observed in the frequency of alleles between the case and control groups. In addition, in LDL-C and total cholesterol in the control group, there was a significant difference between AA and TT genotypes as well as with AA and AT genotypes. However, no correlation was found between the other studied serum parameters and the genotype of individuals in the rs1106197171 polymorphism.
Conclusion: It can be concluded that rs11061971 (+219 A>T) polymorphism is associated with T2D incidence. The findings suggest that AT and TT genotypes in this gene compared to AA genotype increase the risk of diabetes.
Full-Text [PDF 417 kb]
(493 Downloads)
| | Full-Text (HTML) (282 Views)
✅ It can be concluded that rs11061971 (+219 A>T) polymorphism is associated with T2D incidence. The findings suggest that AT and TT genotypes in this gene compared to AA genotype increase the risk of diabetes.
Type of Study: Original Article |
Subject:
Clinical medicine
Received: 2022/11/12 | Accepted: 2023/02/2 | Published: 2023/09/27
Received: 2022/11/12 | Accepted: 2023/02/2 | Published: 2023/09/27
References
1. Illescas-Montes R, Corona-Castro CC, Melguizo-Rodríguez L, Ruiz C. Infectious processes and systemic lupus erythematosus.Immunol. 2019; 158(3):153-60. [DOI:10.1111/imm.13103] [PMID] [PMCID]
2. Pons-Estel GJ, Ugarte-Gil MF. Epidemiology of systemic lupus erythematosus.Expert Rev Clin Immunol. 2017; 13(8):799-814. [DOI:10.1080/1744666X.2017.1327352] [PMID]
3. Riveros Frutos A, Casas I, Rúa-Figueroa I, et al. Systemic lupus erythematosus in Spanish males: a study of the Spanish Rheumatology Society Lupus Registry (RELESSER) cohort. Lupus. 2017; 26(7):698-706. [DOI:10.1177/0961203316673728] [PMID]
4. Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. Ann Rheum Dis. 2016; 75(1):136-41. [DOI:10.1136/annrheumdis-2014-206334] [PMID] [PMCID]
5. Weckerle CE, Niewold TB. The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies. Clin Rev Allergy Immunol. 2011; 40(1):42-9. [DOI:10.1007/s12016-009-8192-4] [PMID] [PMCID]
6. Akbarian M, Faezi ST, Gharibdoost F, et al. Systemic lupus erythematosus in Iran: a study of 2280 patients over 33 years. Int J Rheum Dis. 2010; 13(4):374-9. [DOI:10.1111/j.1756-185X.2010.01547.x] [PMID]
7. Jorge AM, Lu N, Zhang Y, Rai SK, Choi HK. Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014). Rheumatology. 2017; 57(2):337-44. [DOI:10.1093/rheumatology/kex412] [PMID] [PMCID]
8. Organization WHO. WHO QOL Measuring Quality of Life. Geneva, Switzerland: Division of Mental Health and Prevention of Substance Abuse. World Health Organization. 1997.
9. Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken). 2012; 64(2):159-68. [DOI:10.1002/acr.20683] [PMID]
10. da Hora TC, Lima K, Maciel RRBT. The effect of therapies on the quality of life of patients with systemic lupus erythematosus: a meta-analysis of randomized trials. Adv Rheumatol. 2019; 59(1):34. [DOI:10.1186/s42358-019-0074-8] [PMID]
11. Phuti A, Schneider M, Tikly M, Hodkinson B. Living with systemic lupus erythematosus in the developing world. Rheumatol Int. 2018; 38(9):1601-13. [DOI:10.1007/s00296-018-4017-1] [PMID]
12. Sahebari M, Ebrahimabad MJA, Shoraketokanlo AA, Sharbaf HA, Khodashahi M. Efficacy of acceptance and commitment therapy in reducing disappointment, psychological distress, and psychasthenia among Systemic lupus erythematosus (SLE) patients. Iran J Psychiatr. 2019; 14(2):130. [DOI:10.18502/ijps.v14i2.992]
13. Salehpoor G, Rezaei S, Hosseininezhad M. Quality of life in multiple sclerosis (MS) and role of fatigue, depression, anxiety, and stress: A bicenter study from north of Iran. Iran J Nurs Midwife Res. 2014; 19(6):593.
14. Shamekhi Z, Amani R, Habibagahi Z, Namjoyan F, Ghadiri A, Saki Malehi A. A Randomized, double‐blind, placebo‐controlled clinical trial examining the effects of green tea extract on systemic lupus erythematosus disease activity and quality of life. Phytother Res. 2017; 31(7):1063-71. [DOI:10.1002/ptr.5827] [PMID]
15. Zakeri Z, Shakiba M, Narouie B, Mladkova N, Ghasemi-Rad M, Khosravi A. Prevalence of depression and depressive symptoms in patients with systemic lupus erythematosus: Iranian experience. Rheumatol Int.2012; 32(5):1179-87. [DOI:10.1007/s00296-010-1791-9] [PMID]
16. Shakeri H, Arman F, Hossieni M, Omrani HR, Vahdani A, Shakeri J. Depression, anxiety and disease-related variables and quality of life among individuals with systemic lupus erythematosus living in Kermanshah province, Iran. Iran Red Crescent Med J. 2015; 17(12):e31047-e. [DOI:10.5812/ircmj.31047]
17. Hosseini N, Bonakdar ZS, Gholamrezaei A, Mirbagher L. Linguistic validation of the lupusQoL for the assessment of quality of life in Iranian patients with systemic lupus erythematosus. Int J Rheumatol. 2014; 2014:151530. [DOI:10.1155/2014/151530] [PMID] [PMCID]
18. Sutton EJ, Davidson JE, Bruce IN. The systemic lupus international collaborating clinics (SLICC) damage index: a systematic literature review. Semin Arthritis Rheum; 2013:43(3):352-61 [DOI:10.1016/j.semarthrit.2013.05.003] [PMID]
19. Leong KP, Kong KO, Thong BY,et al. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatol (Oxford). 2005; 44(10):1267-76. [DOI:10.1093/rheumatology/keh605] [PMID]
20. Nejat S, Montazeri A, Holakouie Naieni K, Mohammad K, Majdzadeh S. The World Health Organization quality of Life (WHOQOL-BREF) questionnaire: Translation and validation study of the Iranian version. Journal of school of public health and institute of public health research. 2006; 4(4):1-12.
21. Tylka J, Piotrowicz R. Quality of life questionnaire SF-36 -- Polish version. Kardiol Pol. 2009; 67(10:116)6-9.
22. McElhone K, Abbott J, Gray J, Williams A, Teh LS. Patient perspective of systemic lupus erythematosus in relation to health-related quality of life concepts: a qualitative study. Lupus. 2010;19(14):1640-7. [DOI:10.1177/0961203310378668] [PMID]
23. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the systemic lupus international collaborating clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996; 39(3):363-9. [DOI:10.1002/art.1780390303] [PMID]
24. Bruce IN, Keeffe AG, Farewell V, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2014; 74(9):1706. [DOI:10.1136/annrheumdis-2013-205171] [PMID] [PMCID]
25. Mikdashi J, Nived O. Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research. Arthritis Res Ther. 2015; 17(1):183. [DOI:10.1186/s13075-015-0702-6] [PMID] [PMCID]
26. Louthrenoo W, Kasitanon N, Morand E, Kandane-Rathnayake R. Comparison of performance of specific (SLEQOL) and generic (SF36) health-related quality of life questionnaires and their associations with disease status of systemic lupus erythematosus: a longitudinal study. Arthritis Res Ther. 2020; 22(1):8. [DOI:10.1186/s13075-020-2095-4] [PMID] [PMCID]
27. Lai JS, Beaumont JL, Jensen SE, et al. An evaluation of health-related quality of life in patients with systemic lupus erythematosus using PROMIS and Neuro-QoL. Clin Rheumatol. 2017; 36(3):555-62. [DOI:10.1007/s10067-016-3476-6] [PMID]
28. McElhone K, Abbott J, Sutton C, et al. Sensitivity to change and minimal important differences of the lupusQoL in patients with systemic lupus erythematosus. Arthritis Care Res. 2016;68(10):1505-13. [DOI:10.1002/acr.22850] [PMID] [PMCID]
29. Björk M, Dahlström Ö, Wetterö J, Sjöwall C. Quality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus. BMC Musculoskelet Disord. 2015; 1 (16):188. [DOI:10.1186/s12891-015-0621-3] [PMID] [PMCID]
30. Goreshi R, Chock M, Foering K, et al. Quality of life in dermatomyositis. J Am Acad Dermatol. 2011; 65(6):1107-16. [DOI:10.1016/j.jaad.2010.10.016] [PMID] [PMCID]
31. Cipriano E, Ceccarelli F, Massaro L, et al. Joint involvement in patients affected by systemic lupus erythematosus: application of the swollen to tender joint count ratio. Reumatismo. 2015; 67(2):62-7. [DOI:10.4081/reumatismo.2015.828] [PMID]
32. Ceccarelli F, Perricone C, Cipriano E, et al. Usefulness of composite indices in the assessment of joint involvement in systemic lupus erythematosus patients: correlation with ultrasonographic score. Lupus. 2019; 28(3):383-8. [DOI:10.1177/0961203319828527] [PMID]
33. Tani C, Carli L, Stagnaro C, et al. Imaging of joints in systemic lupus erythematosus. Clin Experiment Rheumatol. 2018; 36 Suppl 114(5):68-73.
34. Chaigne B, Chizzolini C, Perneger T, et al. Impact of disease activity on health-related quality of life in systemic lupus erythematosus - a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS). BMC Immunol. 2017; 18(1):17-. [DOI:10.1186/s12865-017-0200-5] [PMID] [PMCID]
35. Jolly M, Toloza S, Goker B, et al. Disease-specific quality of life in patients with lupus nephritis. Lupus. 2018; 27(2):257-64. [DOI:10.1177/0961203317717082] [PMID]
36. Hanly JG, O'Keeffe AG, Su L, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatol (Oxford, England). 2016;55(2):252-62. [DOI:10.1093/rheumatology/kev311] [PMID] [PMCID]
37. Mak A, Tay SH. Outcome of lupus glomerulonephritis: the role of prospective observational cohort studies. Rheumatol (Oxford, England). 2016;55(2):195-6. [DOI:10.1093/rheumatology/kev220] [PMID]
38. Kiani AN, Strand V, Fang H, Jaranilla J, Petri M. Predictors of self-reported health-related quality of life in systemic lupus erythematosus. Rheumatol. 2013; 52(9):1651-7. [DOI:10.1093/rheumatology/ket171] [PMID] [PMCID]
39. Ratanasiripong NT, Ratanasiripong P. Predictive factors of quality of life among systemic lupus erythematosus patients in Thailand: a web-based cross-sectional study. Qual Life Res. 2020; 29(9):2415-23. [DOI:10.1007/s11136-020-02494-6] [PMID]
40. Gaballah NM, El-Najjar AR. Clinical characteristics and health related quality of life (HRQoL) in Egyptian patients with systemic lupus erythematosus. Egypt Rheumatol. 2019; 41(2):117-21. [DOI:10.1016/j.ejr.2018.07.003]
41. Schmeding A, Schneider M. Fatigue, health-related quality of life and other patient-reported outcomes in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2013; 27(3):363-75. [DOI:10.1016/j.berh.2013.07.009] [PMID]
42. Poole JL, Rymek-Gmytrasiewicz M, Mendelson C, Sanders M, Skipper B. Parenting: the forgotten role of women living with systemic lupus erythematosus. Clin Rheumatol. 2012; 31(6):995-1000. [DOI:10.1007/s10067-011-1929-5] [PMID]
43. Elefante E, Tani C, Stagnaro C, et al. Impact of fatigue on health-related quality of life and illness perception in a monocentric cohort of patients with systemic lupus erythematosus. RMD Open. 2020; 6(1):e001133. [DOI:10.1136/rmdopen-2019-001133] [PMID] [PMCID]
44. Shi Y, Li M, Liu L, et al. Relationship between disease activity, organ damage and health-related quality of life in patients with systemic lupus erythematosus: A systemic review and meta-analysis. Autoimmun Rev. 2021; 20(1):102691. [DOI:10.1016/j.autrev.2020.102691] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright Policy
